Elion Therapeutics at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
Elion Therapeutics brings 3 presentations to IDWeek 2026 in Washington. Its program centres on turletricin, its weekly antifungal candidate, and on careers in industry. Early-phase dose escalation trials, including one in people with impaired kidney function, report on the drug's safety.
| Organization | IDWeek 2026 Attendance |
|---|---|
Elion Therapeutics Boston, MA | |
Clinical-stage biotech developing turletricin, a once-weekly polyene antifungal designed to avoid kidney toxicity. | Talk Wed Oct 21 11:05am–12:30pm Poster Thu Oct 22 12:15pm–1:30pm Safety of Turletricin (EL219) in Phase 1 Single-Ascending (SAD) and Multiple-Ascending Dose (MAD)-Escalation and Renal Impairment (RI) Trials Industry Fri Oct 23 8:24am–8:36am Turletricin (EL219/SF001) a novel, once weekly, non-nephrotoxic polyene antifungal Antimicrobials, resistance and stewardship |
Instantly find 20 buyers from Elion Therapeutics
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction